Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in Pigs-Reference-Cited by-同舟云学术

Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in Pigs

Published:2021-10-26 Issue:5 Volume:12 Page:
ISSN:2150-7511
Container-title:mBio
language:en
Short-container-title:mBio

Author:

Lara-Puente Jesús Horacio¹,Carreño Juan Manuel²,Sun Weina²,Suárez-Martínez Alejandro¹,Ramírez-Martínez Luis¹,Quezada-Monroy Francisco¹,Paz-De la Rosa Georgina¹,Vigueras-Moreno Rosalía³,Singh Gagandeep²,Rojas-Martínez Oscar¹,Chagoya-Cortés Héctor Elías⁴,Sarfati-Mizrahi David¹,Soto-Priante Ernesto¹,López-Macías Constantino⁵,Krammer Florian⁶⁷^ORCID,Castro-Peralta Felipa¹,Palese Peter²⁸,García-Sastre Adolfo²⁶⁸⁹^ORCID,Lozano-Dubernard Bernardo¹

Affiliation:

1. Laboratorio Avi-Mex, S. A. de C. V. (Avimex), Iztapalapa, CDMX, Mexico

2. Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA

3. Diagnósticos Clínicos Veterinarios, S. A. de C. V. (DCV), Iztapalapa, CDMX, Mexico

4. Consultora Mextrategy, S. A. S. de C. V., Benito Juárez, CDMX, Mexico

5. Unidad de Investigación Médica en Inmunoquímica, UMAE Hospital de Especialidades del Centro Médico Nacional Siglo XXI. Instituto Mexicano del Seguro Social (IMSS), Cuauhtémoc, CDMX, Mexico

6. The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA

7. Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York, USA

8. Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, USA

9. Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA

Abstract

Several highly efficacious vaccines for SARS-CoV-2 have been developed and are used in the population. However, the current production capacity cannot meet the global demand. Therefore, additional vaccines—especially ones that can be produced locally and at low cost—are urgently needed. This work describes preclinical testing of a SARS-CoV-2 vaccine candidate which meets these criteria.

Funder

HHS | NIH | National Institute of Allergy and Infectious Diseases

Agencia Mexicana de Cooperación Internacional para el Desarrollo

Publisher

American Society for Microbiology

Subject

Virology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/mBio.01908-21

Reference48 articles.

1. A pneumonia outbreak associated with a new coronavirus of probable bat origin

2. A Novel Coronavirus from Patients with Pneumonia in China, 2019

3. SARS-CoV-2 vaccines in development

4. Pan-American Health Organization. 2021. PAHO Director warns that vaccines alone will not stop current COVID-19 surge. Pan-American Health Organization Washington DC. https://www.paho.org/en/news/14-4-2021-paho-director-warns-vaccines-alone-will-not-stop-current-covid-19-surge.

5. A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety evaluation of recombinant Newcastle disease virus expressing IBV multi-epitope chimeric live vaccine;Frontiers in Microbiology;2024-07-31

2. Immunogenicity of intranasal vaccine based on SARS-CoV-2 spike protein during primary and booster immunizations in mice;Human Vaccines & Immunotherapeutics;2024-06-16

3. Rapid production of COVID-19 subunit vaccine candidates and their immunogenicity evaluation in pigs;International Journal of Biological Macromolecules;2024-06

4. Newcastle disease virus vector-based SARS-CoV-2 vaccine candidate AVX/COVID-12 activates T cells and is recognized by antibodies from COVID-19 patients and vaccinated individuals;Frontiers in Immunology;2024-05-30

5. Mucosal Vaccination with a Newcastle Disease Virus-Vectored Vaccine Reduces Viral Loads in SARS-CoV-2-Infected Cynomolgus Macaques;Vaccines;2024-04-10